Do analysts rate ENSC or MAAQ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ensysce Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mana Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation & earnings, ENSC or MAAQ?

Mana Capital Acquisition has lower revenue, but higher earnings than Ensysce Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ensysce Biosciences $5.07M 0.83 -$10.18M -$3.35 N/A Mana Capital Acquisition N/A N/A N/A N/A N/A

Do analysts prefer ENSC or APLT?

Applied Therapeutics has a consensus target price of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Applied Therapeutics is more favorable than Ensysce Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ensysce Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Applied Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Do analysts rate ENSC or NAII?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ensysce Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Natural Alternatives International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend ENSC or AIMD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ensysce Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ainos 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ENSC or AIMD more profitable?

Ensysce Biosciences has a net margin of -250.39% compared to Ainos' net margin of -11,912.10%. Ainos' return on equity of -160.55% beat Ensysce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Ensysce Biosciences -250.39% -766.45% -256.59% Ainos -11,912.10% -160.55% -62.29%

Do analysts recommend ZIVO or ENSC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Ensysce Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Ensysce Biosciences (ENSC) Competitors

$0.27 +0.00 (+0.63%)

Closing price 04:00 PM Eastern

Extended Trading

$0.28 +0.00 (+0.73%)

As of 07:59 PM Eastern

Compare

ENSC vs. MAAQ, APLT, NAII, AIMD, and ZIVO

Should you buy Ensysce Biosciences stock or one of its competitors? MarketBeat compares Ensysce Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ensysce Biosciences include Mana Capital Acquisition (MAAQ), Applied Therapeutics (APLT), Natural Alternatives International (NAII), Ainos (AIMD), and ZIVO Bioscience (ZIVO). These companies are all part of the "pharmaceutical products" industry.

How does Ensysce Biosciences compare to Mana Capital Acquisition?

Ensysce Biosciences (NASDAQ:ENSC) and Mana Capital Acquisition (NASDAQ:MAAQ) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ensysce Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mana Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Mana Capital Acquisition has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -250.39%. Mana Capital Acquisition's return on equity of 0.00% beat Ensysce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ensysce Biosciences	-250.39%	-766.45%	-256.59%
Mana Capital Acquisition	N/A	N/A	N/A

In the previous week, Ensysce Biosciences' average media sentiment score of 0.00 equaled Mana Capital Acquisition'saverage media sentiment score.

Company	Overall Sentiment
Ensysce Biosciences	Neutral
Mana Capital Acquisition	Neutral

Mana Capital Acquisition has lower revenue, but higher earnings than Ensysce Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ensysce Biosciences	$5.07M	0.83	-$10.18M	-$3.35	N/A
Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A

5.6% of Ensysce Biosciences shares are held by institutional investors. Comparatively, 68.4% of Mana Capital Acquisition shares are held by institutional investors. 2.8% of Ensysce Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Mana Capital Acquisition beats Ensysce Biosciences on 4 of the 7 factors compared between the two stocks.

How does Ensysce Biosciences compare to Applied Therapeutics?

Ensysce Biosciences (NASDAQ:ENSC) and Applied Therapeutics (NASDAQ:APLT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

In the previous week, Ensysce Biosciences' average media sentiment score of 0.00 equaled Applied Therapeutics'average media sentiment score.

Company	Overall Sentiment
Ensysce Biosciences	Neutral
Applied Therapeutics	Neutral

Ensysce Biosciences has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, Applied Therapeutics has a beta of 2.08, meaning that its share price is 108% more volatile than the broader market.

Ensysce Biosciences has higher revenue and earnings than Applied Therapeutics. Applied Therapeutics is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ensysce Biosciences	$5.07M	0.83	-$10.18M	-$3.35	N/A
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A

Applied Therapeutics has a consensus target price of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Applied Therapeutics is more favorable than Ensysce Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ensysce Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Applied Therapeutics has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -250.39%. Applied Therapeutics' return on equity of -340.84% beat Ensysce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ensysce Biosciences	-250.39%	-766.45%	-256.59%
Applied Therapeutics	N/A	-340.84%	-175.00%

5.6% of Ensysce Biosciences shares are held by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are held by institutional investors. 2.8% of Ensysce Biosciences shares are held by company insiders. Comparatively, 1.6% of Applied Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Applied Therapeutics beats Ensysce Biosciences on 9 of the 13 factors compared between the two stocks.

How does Ensysce Biosciences compare to Natural Alternatives International?

Ensysce Biosciences (NASDAQ:ENSC) and Natural Alternatives International (NASDAQ:NAII) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Ensysce Biosciences has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market. Comparatively, Natural Alternatives International has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market.

Ensysce Biosciences has higher earnings, but lower revenue than Natural Alternatives International. Natural Alternatives International is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ensysce Biosciences	$5.07M	0.83	-$10.18M	-$3.35	N/A
Natural Alternatives International	$129.86M	0.12	-$13.57M	-$2.39	N/A

5.6% of Ensysce Biosciences shares are owned by institutional investors. Comparatively, 32.4% of Natural Alternatives International shares are owned by institutional investors. 2.8% of Ensysce Biosciences shares are owned by insiders. Comparatively, 20.8% of Natural Alternatives International shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Natural Alternatives International has a net margin of -10.13% compared to Ensysce Biosciences' net margin of -250.39%. Natural Alternatives International's return on equity of -12.21% beat Ensysce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ensysce Biosciences	-250.39%	-766.45%	-256.59%
Natural Alternatives International	-10.13%	-12.21%	-5.30%

In the previous week, Ensysce Biosciences' average media sentiment score of 0.00 equaled Natural Alternatives International'saverage media sentiment score.

Company	Overall Sentiment
Ensysce Biosciences	Neutral
Natural Alternatives International	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ensysce Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Natural Alternatives International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Natural Alternatives International beats Ensysce Biosciences on 7 of the 11 factors compared between the two stocks.

How does Ensysce Biosciences compare to Ainos?

Ensysce Biosciences (NASDAQ:ENSC) and Ainos (NASDAQ:AIMD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

5.6% of Ensysce Biosciences shares are held by institutional investors. 2.8% of Ensysce Biosciences shares are held by insiders. Comparatively, 9.8% of Ainos shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Ensysce Biosciences has a net margin of -250.39% compared to Ainos' net margin of -11,912.10%. Ainos' return on equity of -160.55% beat Ensysce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ensysce Biosciences	-250.39%	-766.45%	-256.59%
Ainos	-11,912.10%	-160.55%	-62.29%

In the previous week, Ainos had 1 more articles in the media than Ensysce Biosciences. MarketBeat recorded 1 mentions for Ainos and 0 mentions for Ensysce Biosciences. Ainos' average media sentiment score of 0.54 beat Ensysce Biosciences' score of 0.00 indicating that Ainos is being referred to more favorably in the news media.

Company	Overall Sentiment
Ensysce Biosciences	Neutral
Ainos	Positive

Ensysce Biosciences has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market. Comparatively, Ainos has a beta of 2.41, suggesting that its stock price is 141% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ensysce Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ainos	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Ensysce Biosciences has higher revenue and earnings than Ainos. Ainos is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ensysce Biosciences	$5.07M	0.83	-$10.18M	-$3.35	N/A
Ainos	$120K	132.06	-$14.77M	-$2.89	N/A

Summary

Ainos beats Ensysce Biosciences on 8 of the 13 factors compared between the two stocks.

How does Ensysce Biosciences compare to ZIVO Bioscience?

ZIVO Bioscience (NASDAQ:ZIVO) and Ensysce Biosciences (NASDAQ:ENSC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

ZIVO Bioscience has a beta of 0.07, indicating that its stock price is 93% less volatile than the broader market. Comparatively, Ensysce Biosciences has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market.

ZIVO Bioscience has higher earnings, but lower revenue than Ensysce Biosciences. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZIVO Bioscience	$15.85K	966.62	-$7.78M	-$1.71	N/A
Ensysce Biosciences	$5.07M	0.83	-$10.18M	-$3.35	N/A

In the previous week, ZIVO Bioscience's average media sentiment score of 0.00 equaled Ensysce Biosciences'average media sentiment score.

Company	Overall Sentiment
ZIVO Bioscience	Neutral
Ensysce Biosciences	Neutral

ZIVO Bioscience has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -250.39%. ZIVO Bioscience's return on equity of 0.00% beat Ensysce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ZIVO Bioscience	N/A	N/A	-2,240.92%
Ensysce Biosciences	-250.39%	-766.45%	-256.59%

12.8% of ZIVO Bioscience shares are held by institutional investors. Comparatively, 5.6% of Ensysce Biosciences shares are held by institutional investors. 48.9% of ZIVO Bioscience shares are held by insiders. Comparatively, 2.8% of Ensysce Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Ensysce Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

ZIVO Bioscience beats Ensysce Biosciences on 7 of the 12 factors compared between the two stocks.

Get Ensysce Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENSC vs. The Competition

Export

Metric	Ensysce Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.17M	$3.41B	$6.43B	$12.54B
Dividend Yield	N/A	2.32%	2.68%	5.81%
P/E Ratio	-0.08	10.87	21.11	22.38
Price / Sales	0.83	330.92	529.68	114.81
Price / Cash	N/A	56.54	27.92	37.84
Price / Book	0.43	8.34	10.85	6.58
Net Income	-$10.18M	$23.80M	$3.56B	$336.75M
7 Day Performance	1.15%	3.63%	0.70%	-0.49%
1 Month Performance	-14.31%	1.77%	0.29%	1.56%
1 Year Performance	-86.49%	58.60%	30.68%	33.78%

Ensysce Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENSC Ensysce Biosciences	0.7973 of 5 stars	$0.27 +0.6%	N/A	-86.2%	$4.17M	$5.07M	N/A	10
MAAQ Mana Capital Acquisition	N/A	$1.97 +0.5%	N/A	-46.6%	$16.01M	N/A	N/A	1	Gap Up
APLT Applied Therapeutics	1.59 of 5 stars	$0.10 flat	$1.00 +870.9%	N/A	$15.86M	$1M	N/A	30
NAII Natural Alternatives International	0.5151 of 5 stars	$2.50 -0.8%	N/A	-19.3%	$15.81M	$129.86M	N/A	290	Gap Up High Trading Volume
AIMD Ainos	0.6668 of 5 stars	$1.88 +2.2%	N/A	-25.5%	$15.69M	$120K	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENSC) was last updated on 6/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ensysce Biosciences (ENSC) Competitors

ENSC vs. MAAQ, APLT, NAII, AIMD, and ZIVO

How does Ensysce Biosciences compare to Mana Capital Acquisition?

Summary

How does Ensysce Biosciences compare to Applied Therapeutics?

Summary

How does Ensysce Biosciences compare to Natural Alternatives International?

Summary

How does Ensysce Biosciences compare to Ainos?

Summary

How does Ensysce Biosciences compare to ZIVO Bioscience?

Summary

Media Sentiment Over Time

ENSC vs. The Competition

Ensysce Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ensysce Biosciences (ENSC) Competitors

ENSC vs. MAAQ, APLT, NAII, AIMD, and ZIVO

How does Ensysce Biosciences compare to Mana Capital Acquisition?

Do analysts rate ENSC or MAAQ?

Is ENSC or MAAQ more profitable?

Does the media favor ENSC or MAAQ?

Which has better valuation & earnings, ENSC or MAAQ?

Do institutionals and insiders believe in ENSC or MAAQ?

Summary

How does Ensysce Biosciences compare to Applied Therapeutics?

Does the media prefer ENSC or APLT?

Which has more volatility and risk, ENSC or APLT?

Which has preferable valuation & earnings, ENSC or APLT?

Do analysts prefer ENSC or APLT?

Is ENSC or APLT more profitable?

Do institutionals & insiders have more ownership in ENSC or APLT?

Summary

How does Ensysce Biosciences compare to Natural Alternatives International?

Which has more risk & volatility, ENSC or NAII?

Which has stronger earnings and valuation, ENSC or NAII?

Do institutionals and insiders hold more shares of ENSC or NAII?

Is ENSC or NAII more profitable?

Does the media prefer ENSC or NAII?

Do analysts rate ENSC or NAII?

Summary

How does Ensysce Biosciences compare to Ainos?

Do institutionals and insiders have more ownership in ENSC or AIMD?

Is ENSC or AIMD more profitable?

Does the media refer more to ENSC or AIMD?

Which has more volatility and risk, ENSC or AIMD?

Do analysts recommend ENSC or AIMD?

Which has stronger earnings & valuation, ENSC or AIMD?

Summary

How does Ensysce Biosciences compare to ZIVO Bioscience?

Which has more risk & volatility, ZIVO or ENSC?

Which has stronger earnings & valuation, ZIVO or ENSC?

Does the media prefer ZIVO or ENSC?

Is ZIVO or ENSC more profitable?

Do institutionals & insiders have more ownership in ZIVO or ENSC?

Do analysts recommend ZIVO or ENSC?

Summary

Media Sentiment Over Time

ENSC vs. The Competition

Ensysce Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools